Patents Assigned to Convert Pharmaceuticals S.A.
  • Prodrugs and medical uses thereof
    Patent number: 12708620
    Abstract: The invention relates to nitrogen mustards bearing substituted piperazine carboxamide and their corresponding pharmaceutically acceptable salts as cytotoxic agents that target tumours and methods of use thereof, alone or in combination with other cancer treatments.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: August 18, 2026
    Assignee: Convert Pharmaceuticals S.A.
    Inventors: Arne Heyerick, Sofie Deschoemaeker, Sophie Thiolloy, Dominique Tersago, Philippe Lambin